Shanghai Junshi Biosciences Co (1877) Fair Value & Analysis
Healthcare · HK · Market cap HK$18.7B
Fair value as of: Jul 2, 2026
From 3 valuation models · updated 9 days ago
Share price +16.7% over the past month.
Price vs Fair Value (12 months)
12‑month range HK$15.37 – HK$36.84 · fair‑value band HK$0.8300 – HK$3.45 · the HK$19.37 price screens above the HK$1.91 fair value. As of Jul 2, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Shanghai Junshi Biosciences Co (1877) currently trades at HK$19.37, while our model-based Fair Value estimate is HK$1.91 — implying the stock looks roughly 90.1% overvalued today. We read business quality at 33/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
Over the trailing twelve months, Shanghai Junshi Biosciences Co generated revenue of HK$2.7B at a net margin of -24.3%. Revenue grew 45.1% year over year. It earns a return on equity of -13.5%. Net debt stands at HK$1.5B. Fundamentals as of Jul 2, 2026
Our scenario range runs from HK$0.8300 (bear case) to HK$3.45 (bull case); at HK$19.37, the current price sits above that range. The share trades about 50% below its 52-week high and 27% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -28% fair-value upside — at -90%, 1877 screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.
About the company
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneous injection which is in phase III clinical trial for the treatment of tumors; JS105, an oral small molecule inhibitor targeting PI3K-a which is in phase III clinical trial to treat gynecological tumors; and JS107, an antibody-drug conjugate which is in phase III clinical trial for the treatment of gastrointestinal cancer. It also develops JS212, JS213, JS207, JS203, JS125, JS214, and JS214 which is in phase I/II clinical trial for the treatment of tumors; JS111, a small molecule inhibitor targeting which is in …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Shanghai Junshi Biosciences Co reported revenue of HK$2.4B in FY2025 versus HK$4.0B in FY2021, a compound −11.8%/yr. Reported net income was −HK$852M in FY2025.
Is 1877 fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$582.92 | R$95.50 | -84% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 724,332 KRW | -28% |
| Alnylam Pharmaceuticals, Inc ALNY | $286.41 | $106.81 | -63% |
| CSL Limited CSL | A$97.91 | A$100.60 | +3% |
| Celltrion, Inc 068270 | 168,500 KRW | 76,943 KRW | -54% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Shanghai Junshi Biosciences Co (1877) undervalued?
What is the fair value of 1877?
What is the quality score of 1877?
What is the revenue of Shanghai Junshi Biosciences Co (1877)?
What is the net profit margin of 1877?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Unlock the full Shanghai Junshi Biosciences Co analysis — and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.